Brief: Update On Igc’S Phase 1 Clinical Trial On Alzheimer’S Patients
Feb 22 (Reuters) - India Globalization Capital Inc IGC.A :
* UPDATE ON IGC’S PHASE 1 CLINICAL TRIAL ON ALZHEIMER’S
PATIENTS
* INDIA GLOBALIZATION CAPITAL INC - ON FEBRUARY 11, CO
COMPLETED
ADMINISTERING FIRST OF THREE LEVELS OF DOSING OF IGC-AD1
Source text for Eikon: ID:nBw6b73BMa
Further company coverage: IGC.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IGC Pharma
See all newsFocus: Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification
Cannabis stocks climb after Trump signs order to ease curbs on marijuana (updated)
Cannabis stocks rise ahead of potential Trump order to ease marijuana restrictions
Brief: IGC Pharma's Unit Enters Sale Of Assets Agreement For $2.7 Million - SEC Filing
Brief: IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment